In this study, we evaluated the in vitro activity of anidulafungin against selected mold isolates. Anidulafungin showed promising activity against Bipolaris spicifera, Exophiala jeanselmei, Fonsecaea pedrosoi, Madurella mycetomatis, Penicillium marneffei, Phialophora verrucosa, Pseudallescheria boydii, Sporothrix schenckii, and Wangiella dermatitidis.
York, N.Y.), and amphotericin B (Bristol-Myers Squibb, Wallingford, Conn.) were dissolved in 100% dimethyl sulfoxide (Fisher Chemicals, Fair Lawn, N.J.) and then were further diluted (1:50) in 2ϫ RPMI 1640 medium (Sigma Chemical Company, St. Louis, Mo.) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer according to the recommendations of National Committee for Clinical Laboratory Standards (NCCLS) approved standard M38-A (16) to yield two times the final strength required for the test. Amphotericin B was diluted 1:50 with 2ϫ antibiotic medium 3 (AM3; BBL, Cockeysville, Md.) buffered with 0.1 M sodium phosphate to pH 7. Final drug concentrations were 0.03 to 16 g/ml for all drugs. Serial dilutions of each drug were dispensed to microdilution plates and stored at Ϫ80°C until use.
In vitro testing was carried out following the NCCLS M38-A method. Briefly, each isolate was grown on potato dextrose agar slants at 35°C for a period of 7 days. The stock suspensions were prepared by covering the mature fungal colonies with 1 ml of sterile 0.85% saline and scraping gently. The turbidity of conidial spore suspensions was measured at 530 nm and adjusted to 80 to 82% transmittance, except for Pseudallescheria boydii and Rhizopus arrhizus, which were adjusted to 68 to 70% transmittance. The adjusted suspensions were diluted in distilled water 1:50 (except P. boydii, diluted 1:25) to obtain a final (2ϫ) inoculum of 0.4 ϫ 10 4 CFU/ml. Microtiter trays were thawed, and 100 l of fungal suspensions was added to each well. Microdilution plates were incubated at 35°C, and MICs were read visually at the optically clear (MIC with 100% inhibition of growth [MIC-0]) and prominent growth inhibition (MIC at which 50% of the isolates tested are inhibited [MIC-2]) endpoints after incubation for 48 and 72 h, or longer if necessary.
All isolates produced enough visible growth after 48 to 72 h, except for Madurella mycetomatis, which produced visible growth at about 120 h. Zygomycetes grew rapidly within 24 h. MIC-2 ranges and median MICs of anidulafungin and MIC ranges and median MICs of voriconazole and amphotericin B at 48 and 72 h are summarized in Table 1 . For the zygomycetes, as recommended in NCCLS standard M38-A, 24-to 48-h MICs are presented because of their rapid growth. For the Anidulafungin demonstrated potent to moderate activity against Bipolaris spicifera (MIC-2 range, 1 to 8 g/ml), Exophiala jeanselmei (0.125 to 2 g/ml), Fonsecaea pedrosoi (0.5 to 4 g/ml), Madurella mycetomatis (1 g/ml), Paecilomyces spp. (0.03 to Ͼ16 g/ml), Penicillium marneffei (2 g/ml), Phialophora verrucosa (0.03 to 0.25 g/ml), Pseudallescheria boydii (2 to 8 g/ml), Sporothrix schenckii (2 to 4 g/ml), and Wangiella dermatitidis (2 to 8 g/ml). It showed no activity against the zygomycetes. None of the three drugs showed in vitro activity against Absidia spp., Alternaria spp., Scedosporium prolificans, and Scopulariopsis brevicaulis. The MICs of amphotericin B were the lowest for most of the zygomycetes. Echinocandins prevent fungal growth by inhibiting ␤-glucan synthesis in the fungal cell wall. Therefore, we might expect echinocandins to have broad-spectrum antifungal activity because of the presence of ␤-glucan in cell wall structures of many different fungal species (Z. Odabasi, V. L. Paetznick, J. R. Rodriguez, E. Chen, M. R. McGinnis, and L. Ostrosky-Zeichner, 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1021, 2003). However, echinocandins have thus far been used only against Aspergillus and Candida spp. Fungi having reduced ␤-glucan in their cell wall, like Cryptococcus and zygomycetes, are usually resistant to echinocandins; thus, the ␤-glucan content of the organism may be at least partially related to the suceptibility to these drugs (12, 22, 32) . Caspofungin has shown activity against Exophiala jeanselmei, Fonsecaea pedrosoi, Paecilomycess variotii, and Scedosporium apiospermum but no activity against Rhizopus arrhizus, Paecilomyces lilacinus, and Scedosporium prolificans (3). This is similar to our findings with anidulafungin. In a previous study, anidulafungin showed variable activity against Bipolaris spp., Pseudallescheria boydii, and Sporothrix schenkii and some activity against three different Phialophora species (6) . We found anidulafungin to be very active against five Phialophora verrucosa isolates. In another previous study, anidulafungin was also found to be active against one Acremonium spp., one Paecilomyces sp., and five Pseudallescheria boydii isolates (22) , which is consistent with our findings.
In summary, against a limited number of isolates in our study, anidulafungin demonstrated promising in vitro activity for a variety of molds for which we have few alternative therapeutic options. Further investigation is warranted.
